Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half

19 Apr 2007

• By Lee Szilagyi

Firm reports first-quarter revenues of over $1 billion.

Related Content

FDA To Review Gilead’s Ambrisentan And Encysive’s Thelin Back-To-Back

16 Feb 2007

Merck R&amp;D Renaissance To Continue With Three NDA Filings In 2007

12 Dec 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.